us to channel the fluid through a 50 or 200 µ
shunt. The Ex-Press helps prevent hypotony,
but the other disadvantages of trabeculectomy
remain. Physicians continue to use this proce-
dure for patients who are failing other thera-
pies, but it has been slowly declining in popu-
larity.
That could change with a new device on the
horizon, the InnFocus by Santen. It bears
resemblance to the Ex-Press in that it allows
fluid to escape and drains into the sub-con-
junctival space and involves an ab externo
incision, but no flap is required and the stent is
longer so hypotony is even less common.
Moreover, it's made out of SIBS, the same
material used for some coronary stents. It's
very biocompatible and cellular material does-
n't stick to it.
Micro Invasive Glaucoma Surgery
(MIGS)
In 2012, a renaissance began in glaucoma
treatment. That's when the FDA approved the
first of 3 new stents that could be implanted
ab interno, or from the inside of the eye.
These new devices offered many advantages.
For one thing, they didn't require time-con-
suming conjunctival manipulation. For anoth-
er, they promised robust but well controlled
outflow. Implanting them required surgical
M a r c h 2 0 1 7 • O U T PA T I E N T S U R G E R Y. N E T • 4 7
9 Orchard, Suite 111
Lake Forest, CA 92630
www.optisurgical.com
info@optisurgical.com
Call AOI for Information
800.576.1266 or
949.580.1266
Instrument Rinse System
®
• For instruments with lumen
and tubing
• Provides consistent rinsing
pressure and volume
regardless of the operator
• Eliminates hand fatigue caused
by repetitive syringe use
• Frees up your hands to perform
other tasks, greatly improving
the speed and efficiency of
your reprocessing department
Still rinsing
with a syringe?
Use the
